These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 22137612)

  • 1. Assessment of ablative margin by unenhanced magnetic resonance imaging after radiofrequency ablation for hepatocellular carcinoma.
    Koda M; Tokunaga S; Miyoshi K; Kishina M; Fujise Y; Kato J; Matono T; Okamoto K; Murawaki Y; Kakite S
    Eur J Radiol; 2012 Oct; 81(10):2730-6. PubMed ID: 22137612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of ablative margin after radiofrequency ablation for hepatocellular carcinoma; comparison between magnetic resonance imaging with ferucarbotran and enhanced CT with iodized oil deposition.
    Koda M; Tokunaga S; Fujise Y; Kato J; Matono T; Sugihara T; Nagahara T; Ueki M; Murawaki Y; Kakite S; Yamashita E
    Eur J Radiol; 2012 Jul; 81(7):1400-4. PubMed ID: 21440397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical usefulness of the ablative margin assessed by magnetic resonance imaging with Gd-EOB-DTPA for radiofrequency ablation of hepatocellular carcinoma.
    Koda M; Tokunaga S; Okamoto T; Hodozuka M; Miyoshi K; Kishina M; Fujise Y; Kato J; Matono T; Sugihara T; Oyama K; Hosho K; Okano J; Murawaki Y; Kakite S; Yamashita E
    J Hepatol; 2015 Dec; 63(6):1360-7. PubMed ID: 26232269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of three-dimensional Gd-EOB-DTPA-enhanced MR fusion imaging with CT fusion imaging in the assessment of treatment effect of radiofrequency ablation of hepatocellular carcinoma.
    Makino Y; Imai Y; Igura T; Hori M; Fukuda K; Sawai Y; Kogita S; Fujita N; Takehara T; Murakami T
    Abdom Imaging; 2015 Jan; 40(1):102-11. PubMed ID: 25052767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of ablative margin by MRI with ferucarbotran in radiofrequency ablation for liver cancer: comparison with enhanced CT.
    Tokunaga S; Koda M; Matono T; Sugihara T; Nagahara T; Ueki M; Murawaki Y; Kakite S; Yamashita E
    Br J Radiol; 2012 Jun; 85(1014):745-52. PubMed ID: 21385915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of Local Tumor Progression after Radiofrequency Ablation (RFA) of Hepatocellular Carcinoma by Assessment of Ablative Margin Using Pre-RFA MRI and Post-RFA CT Registration.
    Yoon JH; Lee JM; Klotz E; Woo H; Yu MH; Joo I; Lee ES; Han JK
    Korean J Radiol; 2018; 19(6):1053-1065. PubMed ID: 30386137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffusion-weighted imaging during MR-guided radiofrequency ablation of hepatic malignancies: analysis of immediate pre- and post-ablative diffusion characteristics.
    Hoffmann R; Rempp H; Schraml C; Schwenzer N; Grözinger G; Blumenstock G; Rothgang E; Pereira PL; Claussen CD; Clasen S
    Acta Radiol; 2015 Aug; 56(8):908-16. PubMed ID: 25182804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiofrequency ablation of the liver: determination of ablative margin at MR imaging with impaired clearance of ferucarbotran--feasibility study.
    Mori K; Fukuda K; Asaoka H; Ueda T; Kunimatsu A; Okamoto Y; Nasu K; Fukunaga K; Morishita Y; Minami M
    Radiology; 2009 May; 251(2):557-65. PubMed ID: 19251941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging evaluation of ablative margin and index tumor immediately after radiofrequency ablation for hepatocellular carcinoma: comparison between multidetector-row CT and MR imaging.
    Kim SM; Shin SS; Lee BC; Kim JW; Heo SH; Lim HS; Jeong YY
    Abdom Radiol (NY); 2017 Oct; 42(10):2527-2537. PubMed ID: 28409202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (> 2 and < 5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion.
    Kim YS; Lee WJ; Rhim H; Lim HK; Choi D; Lee JY
    AJR Am J Roentgenol; 2010 Sep; 195(3):758-65. PubMed ID: 20729457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver.
    Xu PJ; Yan FH; Wang JH; Shan Y; Ji Y; Chen CZ
    J Comput Assist Tomogr; 2010 Jul; 34(4):506-12. PubMed ID: 20657216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety margin of radiofrequency ablation for hepatocellular carcinoma: a prospective study using magnetic resonance imaging with superparamagnetic iron oxide.
    Fukuda K; Mori K; Hasegawa N; Nasu K; Ishige K; Okamoto Y; Shiigai M; Abei M; Minami M; Hyodo I
    Jpn J Radiol; 2019 Jul; 37(7):555-563. PubMed ID: 31102138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-dimensional registration of images obtained before and after radiofrequency ablation of hepatocellular carcinoma to assess treatment adequacy.
    Sakakibara M; Ohkawa K; Katayama K; Imanaka K; Ishihara A; Hasegawa N; Kimura H
    AJR Am J Roentgenol; 2014 May; 202(5):W487-95. PubMed ID: 24758684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ablative margin states by magnetic resonance imaging with ferucarbotran in radiofrequency ablation for hepatocellular carcinoma can predict local tumor progression.
    Koda M; Tokunaga S; Miyoshi K; Kishina M; Fujise Y; Kato J; Matono T; Murawaki Y; Kakite S; Yamashita E
    J Gastroenterol; 2013 Nov; 48(11):1283-92. PubMed ID: 23338488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of hepatocellular carcinoma ablative margins using fused pre- and post-ablation hepatobiliary phase images.
    Takeyama N; Mizobuchi N; Sakaki M; Shimozuma Y; Munechika J; Kajiwara A; Uchikoshi M; Uozumi S; Ohgiya Y; Gokan T
    Abdom Radiol (NY); 2019 Mar; 44(3):923-935. PubMed ID: 30327828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.
    Sun HY; Lee JM; Shin CI; Lee DH; Moon SK; Kim KW; Han JK; Choi BI
    Invest Radiol; 2010 Feb; 45(2):96-103. PubMed ID: 20057319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ablative safety margin depicted by fusion imaging with post-treatment contrast-enhanced ultrasound and pre-treatment CECT/CEMRI after radiofrequency ablation for liver cancers.
    Bo XW; Xu HX; Guo LH; Sun LP; Li XL; Zhao CK; He YP; Liu BJ; Li DD; Zhang K; Wang D
    Br J Radiol; 2017 Oct; 90(1078):20170063. PubMed ID: 28749166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrence-free survival after radiofrequency ablation of hepatocellular carcinoma. A registry report of the impact of risk factors on outcome.
    Zytoon AA; Ishii H; Murakami K; El-Kholy MR; Furuse J; El-Dorry A; El-Malah A
    Jpn J Clin Oncol; 2007 Sep; 37(9):658-72. PubMed ID: 17766723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of radiofrequency ablation margin by MRI-MRI image fusion in hepatocellular carcinoma.
    Wang XL; Li K; Su ZZ; Huang ZP; Wang P; Zheng RQ
    World J Gastroenterol; 2015 May; 21(17):5345-51. PubMed ID: 25954109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there a need for MRI within 24 hours after CT-guided percutaneous thermoablation of the liver?
    Ringe KI; Wacker F; Raatschen HJ
    Acta Radiol; 2015 Jan; 56(1):10-7. PubMed ID: 24445091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.